Top Markets
#1 Black Phoenix Black Phoenix +324.80%
#2 Glidr Glidr +84.34%
#3 Akedo Akedo +57.52%
#4 Gold Park Gold Park +55.04%
#5 Acurast Acurast +30.18%
#6 BasedHype BasedHype +28.28%
#7 Cryptopia Cryptopia +22.67%
#8 Avantis Avantis +19.62%
#9 FGRS (Figure Tokenized Stock) FGRS (Figure Tokenized Stock) +17.72%
#10 MYX Finance MYX Finance +16.77%
Coin of the day
Black Phoenix Black Phoenix
Settings
Language
ENGLISH
Currency
USD
Theme
Pathfinder Cell Therapy, Inc. Pathfinder Cell Therapy, Inc.

Pathfinder Cell Therapy, Inc.

PFND
Rank in Stocks #40882
Pathfinder Cell Therapy, Inc. is an emerging biotechnology firm specializing in... Pathfinder Cell Therapy, Inc. is an emerging biotechnology firm specializing in regenerative medicine. This company is dedicated to pioneering innovative cell-based and associated treatments designed to address a range of illnesses and health issues, particularly those involving localized cellular injury within organs. Its proprietary technology shows promise for tackling conditions such as diabetes, kidney disease, heart attacks (myocardial infarction), and peripheral vascular ailments, among others. Established in 2008, the company maintains its corporate headquarters in Cambridge, Massachusetts.
Share Price
$0.0001
Last synced: 2026-08-12
Market Cap
$66.72K
Change (1 day)
0.00%
Change (1 year)
0.00%
Country
US
Trade Pathfinder Cell Therapy, Inc. (PFND)

Category

Healthcare
Revenue for Pathfinder Cell Therapy, Inc. (PFND)
Revenue in Aug 2026 TTM: 0
According to Pathfinder Cell Therapy, Inc. latest financial reports the company's current revenue (TTM) is 0. In 2026 the company made a revenue of 0 equal to the revenue in the year 2026 that was 0. The revenue is the total amount of income that a company generates by the sale of goods or services. Unlike with the earnings no expenses are subtracted.
Revenue history for Pathfinder Cell Therapy, Inc. from 2026 to 2026
Revenue at the end of each year
Year Revenue Change
Not enough data for the provided dates.
Revenue for similar companies or competitors
Company Revenue Revenue Difference Country
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
 $12.62B -
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
 $6.02B -
NL
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
 - -
CH
Samsung Biologics Co.,Ltd. Samsung Biologics Co.,Ltd.
Samsung Biologics Co.,Ltd.
207940.KS
 - -
KR
UCB S.A. UCB S.A.
UCB S.A.
UCB.BR
 $10.11B -
BE